Cardiovascular Drugs and Therapy : Impact Factor & More
eISSN: 1573-7241pISSN: 0920-3206
Share this on:
Key Metrics
CiteScore 
5.6
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.93
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cardiovascular Drugs and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cardiovascular Drugs and Therapy
Lentinan Attenuates Experimental Atherosclerosis by Regulating Macrophage HCK/GUSB Expression and Amino Acid Metabolic Remodeling.
- 5 Aug 2026
- Cardiovascular drugs and therapy
Stroke Heart Syndrome: Neuroimmune and Metabolic Crosstalk with Conceptual Approaches for Precision Therapeutics.
- 5 Aug 2026
- Cardiovascular drugs and therapy
Endpoint Inconsistency and Overinterpretation of Early Biomarkers After CABG.
- 4 Aug 2026
- Cardiovascular drugs and therapy
PRMT2 Aggravates Pressure Overload-induced Cardiac Remodeling by Promoting Endothelial Phenotypic Transition via Snail1 Methylation.
- 3 Aug 2026
- Cardiovascular drugs and therapy
Evaluating the Role of Andexanet Alfa in Managing Intracranial Hemorrhage in Patients on Vascular-Dose Rivaroxaban: A Clinical Dilemma.
- 1 Aug 2026
- Cardiovascular drugs and therapy
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function - a Meta-Analysis of Contemporary Randomized Controlled Trials.
- 1 Aug 2026
- Cardiovascular drugs and therapy
Lentinan Attenuates Experimental Atherosclerosis by Regulating Macrophage HCK/GUSB Expression and Amino Acid Metabolic Remodeling.
- 5 Aug 2026
- Cardiovascular drugs and therapy
Stroke Heart Syndrome: Neuroimmune and Metabolic Crosstalk with Conceptual Approaches for Precision Therapeutics.
- 5 Aug 2026
- Cardiovascular drugs and therapy
Endpoint Inconsistency and Overinterpretation of Early Biomarkers After CABG.
- 4 Aug 2026
- Cardiovascular drugs and therapy
PRMT2 Aggravates Pressure Overload-induced Cardiac Remodeling by Promoting Endothelial Phenotypic Transition via Snail1 Methylation.
- 3 Aug 2026
- Cardiovascular drugs and therapy
Evaluating the Role of Andexanet Alfa in Managing Intracranial Hemorrhage in Patients on Vascular-Dose Rivaroxaban: A Clinical Dilemma.
- 1 Aug 2026
- Cardiovascular drugs and therapy
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function - a Meta-Analysis of Contemporary Randomized Controlled Trials.
- 1 Aug 2026
- Cardiovascular drugs and therapy
FAQs on Cardiovascular Drugs and Therapy
How long has Cardiovascular Drugs and Therapy been actively publishing? 
What is the publishing frequency of Cardiovascular Drugs and Therapy?
How many articles did Cardiovascular Drugs and Therapy publish last year?
What is the eISSN & pISSN for Cardiovascular Drugs and Therapy?
What is Citescore for Cardiovascular Drugs and Therapy?
What is SNIP score for Cardiovascular Drugs and Therapy?
What is the SJR for Cardiovascular Drugs and Therapy?
Who is the publisher of Cardiovascular Drugs and Therapy?
